U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis

OBJECTIVES: We sought to determine if use of a poly (ADP-ribose) polymerase (PARP) inhibitor is cost effective for maintenance treatment of platinum-sensitive recurrent ovarian cancer. METHODS: A decision analysis model compared 4 maintenance strategies: 1) Observation 2) BRCA germline mutation test...

Full description

Saved in:
Bibliographic Details
Published in:Obstet Gynecol
Main Authors: Dottino, Joseph A., Moss, Haley A., Lu, Karen H., Secord, Angeles A., Havrilesky, Laura J.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7181403/
https://ncbi.nlm.nih.gov/pubmed/30870286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000003171
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items